Low Performance of Protease Inhibitor Monotherapy in Comparison with Standard Triple Regimens
Low Performance of Protease Inhibitor Monotherapy in Comparison with Standard Triple Regimens
José V. Fernández-Montero
Department of Internal Medicine, Complexo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela, Spain
*Correspondence: José V. Fernández-Montero, Email not available
Abstract
Albeit that the introduction of HAART more thanone decade ago represented a hallmark in HIV infectionand remains the gold standard, simpler drugregimens are being sought in an attempt to reduceside effects and enhance compliance. Given theircharacteristic pharmacokinetics, ritonavir-boostedprotease inhibitors (PI) in monotherapy have recentlybeen regarded as a potential alternative option tostandard triple therapy, at least in particular circumstances(Swindell, et al. JAMA. 2006;296:806-14).
